Browsing by Author "Midilli, Kenan"

Now showing 1 - 3 of 3

Evaluation of 2015-2016 MOTAKK HBV DNA and HCV RNA external quality assessment national program results
(Ankara Mikrobiyoloji Kulübü, 2018-10-01) Karataylı, Ersin; Soydemir, Ege; Aksoy, Zeynep Buşra; Kızılpınar, Mehtap; Altay Kocak, Aylin; Karataylı, Senem Ceren; Yurdcu, Esra; Yıldırım, Umut; Guriz, Haluk; Bozdayı, Gülendam; Yurdaydın, Cihan; İlhan, Osman; Yıldırım, Yasin; Bozdayı, A. Mithat; Oğuz, Acelya Yalçıntaş; Barış, Ahmet; Alp, Alpaslan; Aksözek, Alper; Sayıner, Arzu; Karagül, Aydan; Ordu, Aylin; İstanbullu, Aye; Otlu, Barış; Arıdoğan, Buket; Aksu, Burak; Buruk, C. Kurtuluş; Karahan, Ceren; Güney, Çakır; Toksöz, Devrim; Yıldırım, Dilara; Çolak, Dilek; Dağlar, Duygu Eren; Fındık, Duygu; Kas, Elif; Calışkan, Emel; Zeyrek, Fadile Yıldız; Arslan, Fatma; Demir, Feyza; Milletli, Fikriye; Kibar, Filiz; Özdinçer, Furkan; Dündar, Gülnür; Arslan, Hande; Ağça, Harun; Aliskan, Hikmet Eda; Güdücuoğlu, Hüseyin; Fidan, Işıl; Akyar, Isin; Afsar, Ilhan; Kaleli, İlknur; Dönmez, İsmail; YanIk, Kemalettin; Midilli, Kenan; çubukcu, Kivanc; Özdemir, Mehmet; Acar, Melek; Yalinay, Meltem; Kuşkucu, Mert Ahmet; Bakırcı, Mustafa Zahir; Aydın, Neriman; Yılmaz, Neziha; Çeken, Nihan; Ziyade, Nihan; Yılmaz, Nisel; Özgümüş, Osman Birol; Gitmişoğlu, Özlem; Demirgan, Recep; Kesli, Recep; Güçkan, Rıdvan; Sertoz, Ruchan; Akgün, Sadık; Aksaray, Sebahat; Tezcan, Seda; Kaygusuz, Sedat; Gökahmetoğlu, Selma; Meşe, Sevim; Bayik, Seyit Ahmet; Akcalı, Sinem; Gürcan, Saban; Karsligil, Tekin; Us, Tercan; Özekinci, Tuncer; Pilgir, Tulin; Aslan, Uğur; Dinc, Ugur; Coşkun, Umut Safiye Say; Çetinkol, Yeliz; Keskin, Yusuf; Ayaydın, Zeynep; Toraman, Zulal Asçı; MOTAKK HBV HCV Calisma Grubu; AĞCA, HARUN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı; 0000-0002-2651-2034; ISU-9626-2023
MOTAKK, as a national external quality control program has been launched to evaluate the molecular detection of viral infections including HBV DNA and HCV RNA in molecular microbiology diagnostic laboratories in Turkey. This program is prepared in compliance with ISO 17043:2010 (Conformity assessment general requirements for proficiency testing) standards, and aims to take the place of external quality control programs from abroad, contributing to standardization and accuracy of molecular diagnostic tests in our country. The aim of this study was to evaluate 2015 and 2016 results of the MOTAKK External Quality Control Program for HBV DNA and HCV RNA viral load. The calls were announced on the web page of MOTAKK (www.motakk.org). The quality control samples were sent to participating laboratories in 2015 and 2016. Main stocks were prepared from patients with chronic hepatitis B and C who had viral load detection with reference methods according to WHO reference materials for viral load studies to improve quality control sera. From these main stocks, samples with different viral loads were prepared from dilutions of plasma with HBV, HCV, HAV, HIV, Parvovirus B19 and CMV negative serologic markers. Quality control samples were sent to the participating laboratories along with the negative samples in the cold chain. The laboratories accomplished the related tests within 2-3 weeks and entered their results on the MOTAKK web page. These results were analysed according to ISO 13528 (Statistical methods for use in proficiency testing by interlaboratory comparison) and scoring reports were created by a software developed by MOTAKK and sent to participating labs. Each laboratory evaluated their own results in comparison with the other laboratory results, reassessed the tests via observing the distance from the mean result and the reference values. The number of laboratories participating in the HBV DNA and HCV RNA external quality control program was 70-73 in 2015-2016. Participants were able to comply with the program tools, registering, entering results and receiving the results reports problem. In HBV panel, 72.6-89.1% and 84.7-90.3% of the participant laboratories were in 1 standard deviation (SD) in 2015-2016, respectively. In HCV panel, 70.8-89.1% and 84.7-90.3% of the participant laboratories were in 1 SD in 2015-2016, respectively. A national external quality control program for HBV DNA and HCV RNA in Turkey has been prepared for the first time with this project and implemented successfully. All the data provided in the MOTAKK external quality control program final report, compensate all the data provided by the quality control program final reports from abroad; additionally, the report allows comparison of used technologies and commercial products.
Evaluation of 2015-2016 MOTAKK HBV DNA and HCV RNA external quality assessment national program results
(Ankara Microbiology Soc, 2018-10-01) Karatayli, Ersin; Soydemir, Ege; Aksoy, Zeynep Busra; Kizilpinar, Mehtap; Altay Kocak, Aylin; Karatayli, Senem Ceren; Yurdcu, Esra; Yildirim, Umut; Guriz, Haluk; Bozdayi, Gulendam; Yurdaydin, Cihan; Ilhan, Osman; Yildirim, Yasin; Bozdayi, A. Mithat; Oguz, Acelya Yalcintas; Baris, Ahmet; Alp, Alpaslan; Aksozek, Alper; Sayiner, Arzu; Karagul, Aydan; Ordu, Aylin; Istanbullu, Aye; Otlu, Baris; Aridogan, Buket; Aksu, Burak; Buruk, C. Kurtulus; Karahan, Ceren; Guney, Cakir; Toksoz, Devrim; Yildirim, Dilara; Colak, Dilek; Daglar, Duygu Eren; Findik, Duygu; Kas, Elif; Caliskan, Emel; Zeyrek, Fadile Yildiz; Arslan, Fatma; Demir, Feyza; Milletli, Fikriye; Kibar, Filiz; Ozdincer, Furkan; Dundar, Gulnur; Arslan, Hande; Agca, Harun; Aliskan, Hikmet Eda; Guducuoglu, Huseyin; Fidan, Isil; Akyar, Isin; Afsar, Ilhan; Kaleli, Ilknur; Donmez, Ismail; Yanik, Kemalettin; Midilli, Kenan; Cubukcu, Kivanc; Ozdemir, Mehmet; Acar, Melek; Yalinay, Meltem; Kuskucu, Mert Ahmet; Bakici, Mustafa Zahir; Aydin, Neriman; Yilmaz, Neziha; Ceken, Nihan; Ziyade, Nihan; Yilmaz, Nisel; Ozgumus, Osman Birol; Gitmisoglu, Ozlem; Demirgan, Recep; Kesli, Recep; Guckan, Ridvan; Sertoz, Ruchan; Akgun, Sadik; Aksaray, Sebahat; Tezcan, Seda; Kaygusuz, Sedat; Gokahmetoglu, Selma; Mese, Sevim; Bayik, Seyit Ahmet; Akcali, Sinem; Gurcan, Saban; Karsligil, Tekin; Us, Tercan; Ozekinci, Tuncer; Pilgir, Tulin; Aslan, Ugur; Dinc, Ugur; Coskun, Umut Safiye Say; Cetinkol, Yeliz; Keskin, Yusuf; Ayaydin, Zeynep; Toraman, Zulal Asci; AĞCA, HARUN; Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı.; 0000-0002-2651-2034; ISU-9626-2023
MOTAKK, as a national external quality control program has been launched to evaluate the molecular detection of viral infections including HBV DNA and HCV RNA in molecular microbiology diagnostic laboratories in Turkey. This program is prepared in compliance with ISO 17043:2010 (Conformity assessment general requirements for proficiency testing) standards, and aims to take the place of external quality control programs from abroad, contributing to standardization and accuracy of molecular diagnostic tests in our country. The aim of this study was to evaluate 2015 and 2016 results of the MOTAKK External Quality Control Program for HBV DNA and HCV RNA viral load. The calls were announced on the web page of MOTAKK (www.motakk.org). The quality control samples were sent to participating laboratories in 2015 and 2016. Main stocks were prepared from patients with chronic hepatitis B and C who had viral load detection with reference methods according to WHO reference materials for viral load studies to improve quality control sera. From these main stocks, samples with different viral loads were prepared from dilutions of plasma with HBV, HCV, HAV, HIV, Parvovirus B19 and CMV negative serologic markers. Quality control samples were sent to the participating laboratories along with the negative samples in the cold chain. The laboratories accomplished the related tests within 2-3 weeks and entered their results on the MOTAKK web page. These results were analysed according to ISO 13528 (Statistical methods for use in proficiency testing by interlaboratory comparison) and scoring reports were created by a software developed by MOTAKK and sent to participating labs. Each laboratory evaluated their own results in comparison with the other laboratory results, reassessed the tests via observing the distance from the mean result and the reference values. The number of laboratories participating in the HBV DNA and HCV RNA external quality control program was 70-73 in 2015-2016. Participants were able to comply with the program tools, registering, entering results and receiving the results reports problem. In HBV panel, 72.6-89.1% and 84.7-90.3% of the participant laboratories were in 1 standard deviation (SD) in 2015-2016, respectively. In HCV panel, 70.8-89.1% and 84.7-90.3% of the participant laboratories were in 1 SD in 2015-2016, respectively. A national external quality control program for HBV DNA and HCV RNA in Turkey has been prepared for the first time with this project and implemented successfully. All the data provided in the MOTAKK external quality control program final report, compensate all the data provided by the quality control program final reports from abroad; additionally, the report allows comparison of used technologies and commercial products.
Investigation of ganciclovir resistance in cytomegalovirus isolates by phenotypic and genotypic methods
(Ankara Mikrobiyoloji, 2023-07-01) Sarınoğlu, Rabia Can; Çolak, Dilek; Küpesiz, Osman Alphan; Kuşkuçu, Mert Ahmet; Yalçın, Koray; Saglık, İmran; Mutlu, Derya; Midilli, Kenan; Peker, Bilal Olcay; Özhak, Betil; Özkul, Aykut; Foldes, Kataline; SAĞLIK, İMRAN; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Mikrobiyoloji Anabilim Dalı; 0000-0003-0864-4989; A-4970-2019
Ganciclovir-resistant cytomegalovirus (CMV) strains are reported following long-term antiviral agent use, especially for immune-suppressive patients. In this study, it was aimed to investigate the mutations in the UL97 gene of CMV, which causes ganciclovir (GCV) resistance by genotypic and phenotypic methods in patients who developed CMV infection following hematopoietic cell (HCT) or solid organ transplantation (SOT). Thirty patients who had HCT or SOT in Mediterranean University Hospital and developed CMV infection during routine follow-up with a viral load of CMV over 1000 copies/mL were included in the study. CMV DNA was analyzed by an automated system (Cobas Ampliprep/COBAS TaqMan CMV Test, Roche Diagnostics, Germany) quantitatively. DNA sequence analysis of the regions including codons 420-664 in the UL97 gene region was done by the Sanger sequencing method to detect mutations causing antiviral resistance and compared with defined mutations. In order to investigate antiviral resistance by phenotypic methods, heparinized blood samples of the patients were collected, 'buffy coat (leukocyte layer)' was inoculated into MRC-5 cells by centrifugation method and CMV growth in these cells was controlled with monoclonal antibodies when growth was detected, virus titer was determined and plaque reduction test was applied as recommended. It was determined that 22 of the 30 patients were HCT recipients and eight were SOT (five kidney, three liver) recipients. When the CMV serology pattern of the patients was evaluated before transplantation, 29 (96.7%) patients were found to be seropositive and one (3.3%) patient was found to be seronegative. Totally, nine CMV UL97 mutations were detected in seven (23.3%) pediatric patients who had HCT, including six seropositive and one seronegative case. In addition, one mutation (D605E) not known to cause GCV resistance was detected in a seronegative recipient and three previously unidentified mutations were detected (1474T, F499S, V559A) in a seronegative recipient. Five of the mutations defined were UL97 mutations with a defined clinical resistance against GCV in each of the five recipients (C603W, C592G, H520Q, M460V, A594T). In the plaque reduction test using 3 mu M, 12 mu M, 48 mu M and 96 mu M concentrations of GCV in CMV strains, the IC50 value was determined to be >= 8 mu M for the five CMV strains, and the phenotypic presence of GCV resistance was shown. Clinical resistance associated with CMV UL97 mutation was detected in five (22.7%) of 22 patients who had HCT. GCV resistance was also demonstrated in these patients by phenotypic methods. No UL97 mutation was detected in the patients who had SOT.